Eskildsen P G, Svendsen P A, Vang L, Nerup J
Acta Endocrinol (Copenh). 1978 Apr;87(4):687-700. doi: 10.1530/acta.0.0870687.
Treatment with bromocriptine, 30-55 mg daily, in 13 acromegalics for 1-15 months, resulted in a 60% decrease in growth hormone secretion, as judged from the excretion of growth hormone in 24-h urine. Normal excretion was obtained in 10 patients, while 1 patient showed no response. The plasma growth hormone response to O-GTT was improved, but not normalized, in 4 of 7 patients treated for more than 6 months, and marked glucosuria disappeared in two diabetics. While the secretion of TSH, LH and FSH was unchanged, the prolactin secretion was inhibited. The urine excretion of free cortisol showed a 30% decrease, possibly due to a direct effect of bromocriptine on the ACTH-secretion. Hypercalcaemia was never seen, but the initial hypercalcuria showed a modest decrease without measurable changes in the creatinine clearance. The subjective relief during long-term treatment was marked in 10 of 11 patients and the dominating symptoms disappeared in 40-67%, whereas heal-pad thickness, enlarged sellae, and visual fields remained unchanged. No serious side effects were observed. Treatment with bromocriptine seems effective and should be considered as a remedy amongst others, in suitable cases of acromegaly.
对13例肢端肥大症患者每日给予30 - 55毫克溴隐亭治疗1 - 15个月,根据24小时尿中生长激素排泄量判断,生长激素分泌减少了60%。10例患者排泄恢复正常,1例无反应。7例治疗超过6个月的患者中,有4例对口服葡萄糖耐量试验(O - GTT)的血浆生长激素反应有所改善但未恢复正常,2例糖尿病患者的明显糖尿消失。促甲状腺激素(TSH)、促黄体生成素(LH)和促卵泡生成素(FSH)的分泌未变,但催乳素分泌受到抑制。游离皮质醇的尿排泄量减少了30%,可能是溴隐亭对促肾上腺皮质激素(ACTH)分泌有直接作用所致。从未出现高钙血症,但最初的高钙尿症有适度减轻,肌酐清除率无明显变化。11例患者中有10例在长期治疗期间主观症状明显缓解,40 - 67%的主要症状消失,而足跟垫厚度、蝶鞍增大和视野保持不变。未观察到严重副作用。溴隐亭治疗似乎有效,在合适的肢端肥大症病例中应作为一种治疗方法予以考虑。